TABLE 2.
Canada (n=1976) | British Columbia (n=164) | Prairies* (n=382) | Ontario (n=787) | Quebec (n=509) | Maritimes†(n=134) | |
---|---|---|---|---|---|---|
Diabetes‡, % | 44.0 | 49.7 | 34.9§ | 45.7 | 40.6 | 61.9§ |
Hypertension¶, % | 77.6 | 85.3** | 71.3** | 80.2** | 77.0 | 69.9** |
Hypercholesterolemia, % | 84.6 | 88.7 | 79.5** | 85.4 | 87.2 | 83.1 |
Abdominal obesity††, % | 53.5 | 48.8 | 58.9** | 49.0** | 50.3 | 61.2** |
Overweight/obese (BMI ≥25 kg/m2), % | 75.4 | 75.7 | 82.0** | 75.1 | 70.3** | 78.9 |
Smoking, % | ||||||
Former‡‡ | 44.2 | 48.3 | 50.0 | 43.4 | 46.3 | 49.7 |
Current§§ | 13.5 | 7.5** | 10.7** | 11.9** | 19.6§ | 19.0§ |
Modified metabolic syndrome¶¶, % | 29.3 | 21.7** | 26.0 | 27.6 | 32.0 | 39.1** |
Impaired fasting glucose***, % | 22.8 | 27.2 | 21.7 | 22.4 | 22.5 | 24.4 |
The values for hypertension, hypercholesterolemia, abdominal obesity, body mass index (BMI), smoking, modified metabolic syndrome and impaired glucose tolerance are adjusted for age and sex. The overall P-values across the regions were not significant for former smoking and impaired fasting glucose; therefore, no pair-wise comparisons were performed.
Alberta, Manitoba and Saskatchewan;
Newfoundland and Labrador, Prince Edward Island, Nova Scotia and New Brunswick;
Patients with type 1 or 2 diabetes currently treated with hypoglycemic agents or a history of diabetes;
P<0.001;
Patients with systolic blood pressure ≥150 mmHg despite therapy for ≥3 months or a history of hypertension;
0.001<P<0.05;
Men: waist circumference ≥102 cm; women: waist circumference ≥88 cm;
≥5 cigarettes/day (mean) >1 month before enrolment;
≥5 cigarettes/day (mean) within 1 month of enrolment;
Patients with ≥3 of the following: abdominal obesity, triglycerides ≥1.7 mmol/L, blood pressure ≥130/85 mmHg, fasting glucose >6.1 mmol/L;
Patients with fasting glucose >5.6 mmol/L and <7.0 mmol/L